HDAC6 Regulates Epidermal Growth Factor Receptor (EGFR) Endocytic Trafficking and Degradation in Renal Epithelial Cells

Wei Liu1,3,4, Lucy X. Fan1,3, Xia Zhou1,3, William E. Sweeney, Jr.1,3, Ellis D. Avner1,2,3, Xiaogang Li1,2,3

1 Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, United States of America, 2 Department of Physiology, Medical College of Wisconsin, Milwaukee, Wisconsin, United States of America, 3 Children's Research Institute, Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States of America, 4 Department of Nephrology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China

Abstract

We present for the first time that histone deacetylase 6 (HDAC6) regulates EGFR degradation and trafficking along microtubules in Pkd1 mutant renal epithelial cells. HDAC6, the microtubule-associated α-tubulin deacetylase, demonstrates increased expression and activity in Pkd1 mutant mouse embryonic kidney cells. Targeting HDAC6 with a general HDAC inhibitor, trichostatin (TSA), or a specific HDAC6 inhibitor, tubacin, increased the acetylation of α-tubulin and downregulated the expression of EGFR in Pkd1 mutant renal epithelial cells. HDAC6 was co-localized with ELF-induced endocytic EGFR and endosomes, respectively. Inhibition of the activity of HDAC6 accelerated the trafficking of EGFR from early endosomes to late endosomes along the microtubules. Without EGFR stimulation EGFR was randomly distributed while after stimulation with EGF for 30 min, EGFR was accumulated around α-tubulin labeled microtubule bundles. These data suggested that the Pkd1 mutation induced upregulation of HDAC6 might act to slow the trafficking of EGFR from early endosomes to late endosomes along the microtubules for degradation through deacetylating α-tubulin. In addition, inhibition of HDAC activity decreased the phosphorylation of ERK1/2, the downstream target of EGFR axis, and normalized EGFR localization from cell surface to intracellular vesicles. Thus, targeting HDAC6 to downregulate EGFR activity may provide a potential therapeutic approach to treat polycystic kidney disease.

Citation: Liu W, Fan LX, Zhou X, Sweeney WE Jr, Avner ED, et al. (2012) HDAC6 Regulates Epidermal Growth Factor Receptor (EGFR) Endocytic Trafficking and Degradation in Renal Epithelial Cells. PLoS ONE 7(11): e49418. doi:10.1371/journal.pone.0049418

Editor: Bin He, Baylor College of Medicine, United States of America

Received June 13, 2012; Accepted October 7, 2012; Published November 13, 2012

Copyright: © 2012 Liu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: X. Li acknowledges support from the Polycystic Kidney Disease Research and Education Foundation grant, Children’s Research Institute grant and National Institutes of Health grant R01DK084097. E.D. Avner acknowledges support from National Institutes of Health grant P50DK079306 (RCEPN). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: E-mail: xxli@mcw.edu

Introduction

Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disease caused by mutations in either PKD1 or PKD2 and is characterized by the formation and progressive growth of cystic lesions that ultimately destroy normal renal parenchyma.[1,2,3] Cyst growth is the result of sustained proliferation of incomplete or de-differentiated epithelial cells and accumulation of fluid within the cysts.[3]

ErbB receptor tyrosine kinases (EGF receptor or EGFR, ErbB2, ErbB3, and ErbB4) and their ligands play important roles in renal development, in renal electrolyte homeostasis and tubule repair following injury.[4,5,6,7,8,9,10] EGFR is normally sorted to apical to basolateral in mature tubular epithelial cells.[8] However, numerous primary PKD causing mutations alter EGFR polarity, leading to increased apical expression and activity.[11] Cystic epithelial cells from ADPKD patients are unusually susceptible to the proliferative stimulus of EGF. EGF and EGF-like ligands are secreted into the apical medium of mature cystic epithelial cells and are present in cyst fluid from ADPKD patients.[12,13] Thus, in cystic epithelia, both receptors (ErbB1 and ErbB2) and ligands are expressed on the same side of the cell leading to sustained mitogenic signaling. In addition, increased expression of ErbB2 leads to the formation of ErbB1/ErbB2 heterodimers that also slows internalization and receptor degradation.[14]

Inhibition of EGFR tyrosine kinase activity either genetically or pharmacologically significantly reduces renal cyst formation and improves renal function in rodent models of PKD.[7,11,15] These observations suggest that persistent EGF signaling from the apical cell surface of renal epithelia is a primary disease progression factor in PKD. However, the mechanism(s) involved in EGF mediated EGFR stability and endocytic trafficking in cystic epithelial cells is unknown.

Ligand activated EGFR complexes on the apical cell surface are internalized into apical sorting endosomes (ASE) and apical recycling endosomal (AREs) intermediates and trafficked through a series of endocytic compartments where they are either recycled or sorted for proteolytic degradation in the lysosome.[16] Aberrant regulations of these complex sorting pathways have been linked to the development and progression of PKD.[14]

Microtubules, together with the microtubule-based motor proteins, kinesin and cytoplasmic dynein, are involved in sorting and transport of early endocytic vesicles to later stage endocytic compartments.[17,18] Recent studies suggest that acetylation of α-tubulin, the component of microtubules, affects the stability of
HDAC6 Regulates EGFR Trafficking

HDAC6 Expression is Increased in Pkd1 Mutant Kidney Epithelial Cells

Recent evidence suggest that sorting and transport of early endocytic cargo to later stage endocytic compartments require microtubules, and HDAC6 may be involved in this process by regulating the stability of microtubules through deacetylation of α-tubulin.[16,20] We found that HDAC6 was up-regulated in Pkd1 mutant renal epithelial cells. We further found that the stability of microtubules affected the reactive pattern of EGFR level after EGF stimulation in Pkd1 mutant kidney epithelial cells. Furthermore, HDAC6 inhibition leads to the stimulation of microtubule-dependent transport of EGFR containing vesicles and the degradation of EGFR, and normalizes EGFR localization from apical to basolateral.

Results

HDAC6 Regulates EGFR Trafficking in Renal Epithelial Cells

To investigate the connection between HDAC6 and EGFR endocytic trafficking in renal epithelial cells, we first examined the association of HDAC6 with endocytic EGFR. Murine inner medullary collecting duct (mIMCD3) cells were stimulated with EGF for 10 minutes, and EGFR labeled with EGF-Alexa Fluor 488 co-localized on the early endosomes labeled with EEA1, an early endosome marker (Fig. 4A). These results suggest that HDAC6 interacts with the early endosomal compartment and endocytic EGFR. After cells were stimulated with EGF for 60 minutes, both HDAC6 and EGFR were colocalized with later endosomes labeled by LAMP2 (Fig. 4D-4F). Colocalization of HDAC6 with EGFR as well as early and later endosomes was also confirmed in postnatal Pkd1 homozygous PN24 cells stimulated with EGF for 10 and 60 minutes (Fig. 5A-5F). In addition, we found that without EGF stimulation EGFR was randomly distributed in Pkd1 wild type and mutant MEK cells decreased the expression of EGFR and increased the acetylation of α-tubulin in MEK cells compared to the control MEK cells transduced with the empty vector (Fig. 3A and 3B). In addition, we found that knockdown of HDAC6 with shRNA did not reduce EGFR expression at mRNA level in Pkd1 null cells (Fig. 3C). These results suggested that HDAC6 might regulate the degradation of EGFR through deacetylation of α-tubulin.

Inhibition of HDAC6 Activity with Tubacin, a Specific HDAC6 Inhibitor, or TSA, a Pan HDAC Inhibitor, Decreased the Expression of EGFR in Renal Epithelial Cells

EGFR has been found over-expressed and hyper-activated in human ADPKD epithelia and in mouse models of ADPKD.[3] To investigate whether the upregulated HDAC6 affected EGFR levels in kidney epithelial cells, we inhibited HDAC6 activity with either tubacin or TSA. We found that treatment with either tubacin or TSA decreased the levels of EGFR but increased the acetylation of α-tubulin in Pkd1 wild type and mutant kidney epithelial cells compared to untreated control cells (Fig. 2A-F). It is interesting to note that TSA treatment decreased the levels of EGFR in both Pkd1 wild type and mutant MEK cells while tubacin treatment only decrease the levels of EGFR in Pkd1 mutant MEK cells (Fig. 2A and 2B). In addition, we found that TSA treatment significantly increased the acetyl-α-tubulin staining in Pkd1 wild type and mutant MEK cells as well as in PH2 and PN24 cells (data not show). Furthermore, knockdown of HDAC6 with pGIPZ lentiviral vector mediated HDAC6 shRNA in both Pkd1 wild type and mutant MEK cells decreased the expression of EGFR and increased the acetylation of α-tubulin in MEK cells compared to the control MEK cells transduced with the empty vector (Fig. 3A and 3B). In addition, we found that knockdown of HDAC6 with shRNA did not reduce EGFR expression at mRNA level in Pkd1 null cells (Fig. 3C). These results suggested that HDAC6 might regulate the degradation of EGFR through deacetylation of α-tubulin.
HDAC activity accelerated the transport of the activated EGFR from the early endosomes to late endosomes/lysosomes.

Microtubule Stability Affected EGF Induced EGFR Degradation

Deacetylation of α-tubulin by HDAC6 has been reported to destabilize microtubules and decrease motor binding.[19,24] To determine whether microtubule stability affects EGFR degradation in renal epithelial cells, we treated Pkd1 wild-type (WT) and Pkd1null/null (Null) MEK cells as well as postnatal Pkd1 heterozygous PH2 cells and homozygous PN24 cells. The activity of HDAC6 in the above cells was quantified from three independent immunoblots and was standardized to actin. **p < 0.01. (B) The activity of HDAC6 in Pkd1 wild-type (WT) and Pkd1null/null (Null) MEK cells as well as postnatal Pkd1 heterozygous PH2 cells and homozygous PN24 cells. The activity of HDAC6 was increased about 7.8 fold in Pkd1null/null (Null) MEK cells and 4.8 fold in postnatal Pkd1 homozygous PN24 cells compared with that in Pkd1 wild type MEK cells and postnatal Pkd1 heterozygous PH2 cells, respectively. The HDAC6 activity assay was performed in three independent experiments. * p < 0.05, ** p < 0.01. (C) Western blotting analysis of the expression of HDAC6 in Pkd1 wild type and Pkd1 hypomorphic homozygous (Pkd1nl/nl) kidney tissues collected at postnatal days 7, 14, and 21. The relative expression levels of HDAC6 in different kidneys were standardized to actin and were presented in the lower panel. (D) Immunohistochemistry of HDAC6 in kidney sections from Pkd1 wild type and Pkd1nl/nl mice harvested at postnatal day 28. Scale bar, 20 μm.

doi:10.1371/journal.pone.0049418.g001

Figure 1: HDAC6 was up-regulated in Pkd1 mutant renal epithelial cells and kidney tissues. (A) Western blotting analysis of the expression of HDAC6 in Pkd1 wild-type (WT) and Pkd1null/null (Null) MEK cells as well as postnatal Pkd1 heterozygous PH2 cells and homozygous PN24 cells. The expression of HDAC6 in the above cells was quantified from three independent immunoblots and was standardized to actin. ** p < 0.01. (B) Western blotting analysis of the expression of HDAC6 in Pkd1 wild-type (WT) and Pkd1null/null (Null) MEK cells as well as postnatal Pkd1 heterozygous PH2 cells and homozygous PN24 cells. The activity of HDAC6 was increased about 7.8 fold in Pkd1null/null (Null) MEK cells and 4.8 fold in postnatal Pkd1 homozygous PN24 cells compared with that in Pkd1 wild type MEK cells and postnatal Pkd1 heterozygous PH2 cells, respectively. The HDAC6 activity assay was performed in three independent experiments. * p < 0.05, ** p < 0.01. (C) Western blotting analysis of the expression of HDAC6 in Pkd1 wild type and Pkd1 hypomorphic homozygous (Pkd1nl/nl) kidney tissues collected at postnatal days 7, 14, and 21. The relative expression levels of HDAC6 in different kidneys were standardized to actin and were presented in the lower panel. (D) Immunohistochemistry of HDAC6 in kidney sections from Pkd1 wild type and Pkd1nl/nl mice harvested at postnatal day 28. Scale bar, 20 μm.

doi:10.1371/journal.pone.0049418.g001

HDAC activity accelerated the transport of the activated EGFR from the early endosomes to late endosomes/lysosomes.
Inhibition of HDAC Activity Decreased the Phosphorylation of ERK and Normalized EGFR Localization from Apical to Basolateral in Pkd1 Knockout Mouse Kidneys

The EGFR axis is considered to act primarily through activation of the MAPK (RAS/RAF/MEK/ERK) pathway.[15] Since inhibition of HDAC6 activity increased the degradation of EGFR in renal epithelial cells, we suspected that it might also affect EGFR mediated ERK activation characterized with the levels of the phosphorylation of ERK1/2. To support this hypothesis, we found that knockdown HDAC6 with shRNA (Fig. 10A) or inhibition of HDAC6 activity with TSA (Fig. 10B) demonstrated a developmental decrease in EGFR and correlated with a substantial decreased phospho-ERK1/2 in cystic epithelial cells treated with EGF.

The mislocalization of the EGFR from basolateral to apical is known to occur in kidneys of both humans and mice and is a common end point associated with several different forms of polycystic kidney disease that are initiated by mutations in different genes.[7] We provided evidence that upregulated HDAC6 regulated EGFR endocytic trafficking and degradation in cystic epithelial cells. We suspected that upregulated HDAC6 might also contribute to the mislocalization of the apical EGFR on cyst lining epithelia. To test this hypothesis, we treated Pkd1+/-;Ksp-cre pups with 0.5 μg/g TSA or DMSO (control) daily from postnatal day 3 (P3) to P6 and harvested the kidneys at postnatal day 7 (P7). Immunohistochemical staining of the control DMSO treated kidneys illustrates the expression of EGFR on apical cell surfaces of cystic epithelia (Fig. 10C). In contrast, treatment with TSA significantly increased the basolateral localization of EGFR on cystic epithelia (Fig. 10D), which suggested that inhibition of HDAC activity could normalize the mislocalized EGFR from apical to basolateral.

Discussion

In this study, we provided the first evidence that 1) HDAC6 regulates EGFR intracellular trafficking and degradation in renal epithelial cells through HDAC6 mediated α-tubulin deacetylation and microtubule stability; 2) inhibition of HDAC activity normalizes apical EGFR to basolateral in Pkd1 conditional knockout mouse model. We found that HDAC6 was up-regulated in Pkd1 mutant MEK cells and in Pkd1 hypomorphic homozygous (Pkd1nl/nl) kidney tissues (Fig. 1A–1D). Pharmacologic and shRNA mediated inhibition of HDAC6 decreased the levels of EGFR in renal epithelial cells (Fig. 2 and 3). We further found that HDAC6 regulated EGFR intracellular trafficking and degradation along microtubules in normal and mutant renal epithelial cells by mediating microtubule acetylation and stability since 1) inhibition...
of HDAC6 activity by pharmacological and shRNA mediated inhibition increased EGFR endocytic trafficking from early endosomes to later endosomes and increased the degradation of EGFR (Fig. 3 and 7); 2) treatment with nocodazole, which depolymerized microtubules, decreased the degradation of EGFR in Pkd1 mutant MEK cells stimulated with EGF (Fig. 9); 3) pharmacological and shRNA mediated inhibition of HDAC6 also decreased the expression of phospho-ERK1/2, a EGFR axis mediated downstream target (Fig. 10A and 10B). In addition, inhibition of HDAC activity with TSA normalized the localization of EGFR from apical to basolateral of the cystic epithelial cells in Pkd1 conditional knockout mouse kidneys (Fig. 10C and 10D). Thus, targeting HDAC6 to downregulate EGFR and its downstream targets as well as to normalize its
localization from apical to basolateral may be a potential therapeutic approach for polycystic kidney disease.

Recent studies suggest that sorting and transport of early endocytic cargos to later stage endocytic compartments require
microtubules, and HDAC6 may be involved in this process since HDAC6 destabilizes microtubules by deacetylating α-tubulin.[16,19,20] Inactivation of HDAC6 leads to dramatic stabilization and accumulation of acetylated microtubules.[24] Enhanced

Figure 5. HDAC6 associated with the endosomal compartments in PN24 cells. (A) PN24 cells were serum-starved overnight and treated with 80 ng/ml EGF-Alexa Fluor 488 for 10 min. After that, cells treated with 0.005% saponin were stained with anti EEA1 antibody. Image in zoom shows the example of early endosomes stained with EEA1 (red) colocalized with EGFR (green). (B) Serum-starved PN24 cells were treated with 100 ng/ml EGF for 10 min and then stained with anti-HDAC6 and EEA1 antibodies. Image in zoom shows the example of early endosomes stained with EEA1 (red) colocalized with HDAC6 (green). (C) PN24 cells were treated and processed as in (A) except using anti-HDAC6 antibody. Image in zoom shows the colocalization of EGFR (green) with HDAC6 (red). (D) PN24 cells were treated with 80 ng/ml EGF-Alexa Fluor 488 for 60 min and then stained with anti-LAMP2 antibody. Image in zoom shows the colocalization of EGFR (green) with later endosomes stained with LAMP2 (red). (E) PN24 cells were treated with 100 ng/ml EGF for 60 min and then stained with anti-HDAC6 and anti-LAMP2 antibodies. Image in zoom shows the example of later endosomes stained with LAMP2 (red) colocalized with HDAC6 (green). (F) PN24 cells were treated and processed as in (D) except using anti-HDAC6 antibody. Image in zoom shows the example of the colocalization of EGFR (green) with HDAC6 (red). doi:10.1371/journal.pone.0049418.g005
microtubule stability leads to the recruitment of molecular motors kinesin-1 and cytoplasmic dynein to microtubules thereby stimulating anterograde and retrograde vesicle transport including EGF stimulated EGFR.[17] The increased expression of HDAC6 and mislocalization of EGFR in cystic renal epithelial cells led us to explore the relationship between HDAC6 and EGFR in cystic epithelial cells. The data presented in this study demonstrate that HDAC6 contributes to increased expression of EGFR by disrupting microtubule mediated EGFR degradation in cystic epithelial cells. Our results show that inhibition of HDAC6 activity with TSA or HDAC6 shRNA significantly decreased the levels of EGFR and also decreased the EGFR axis mediated phosphorylation of ERK1/2 in Pkd1 mutant renal epithelial cells. These data suggest that upregulation of HDAC6 may play a role in upregulating apical EGFR stability leading to prolonged EGFR signaling that facilitates cyst formation.

Previous reports from our laboratory demonstrated that inhibition of HDAC activity with TSA prevent renal cyst formation through targeting MEF2C or Id2 signaling, respectively.[25,26] Our results that inhibition of HDAC activity with TSA could significantly normalize the mislocalized EGFR from apical to basolateral suggested a third possible mechanism for HDAC in mediating cyst development.

In sum, our study identified HDAC6 as a key component of the endocytic trafficking network in renal epithelial cells. The most exciting result related to translational application is that inhibition of HDAC6 activity with its specific inhibitor, tubacin, decreased the levels of EGFR and might also normalize the mislocalized EGFR in Pkd1 mutant MEK cells. Thus, targeting HDAC6 to downregulate EGFR and also normalize EGFR localization may be a potential therapeutic approach to treat polycystic kidney disease.

**Concise Methods**

**Cell Culture and Reagents**

IMCD3 (murine inner medullary collecting duct) cells, HEK-293T cells were maintained at 37°C in 5% CO2 in DMEM (Invitrogen, CA) supplemented with 10% fetal bovine serum (FBS). Dolichos biflorus agglutinin (DBA) positive Pkd1 wild type and Pkd1 null cells mouse embryonic kidney (MEK) cells were maintained as previously described.[27] Pkd1 heterozygous PH2 and homozygous PN24 cells were kindly provided by Dr. Stefan Somlo (Yale University).[28] In brief, Pkd1 cell lines were derived from a single Pkd1floxflox carrying a conditionally immortalizing, temperature and interferon-γ responsive transgene (H-2Kb-tsA58; ImmortoMouse, Charles River). Pkd1−/− were produced from Pkd1floxflox−/− cells by transient transfection with a plasmid expressing the Cre recombinase. Passage numbers were kept below 20 for all cell lines. Cells were maintained in DMEM/F12 supplemented with 10% FBS and γ-interferon (5 U/ml; Sigma-Aldrich, MO) at 33°C and 5% CO2.[28] Trichostatin A (TSA), cycloheximide, nocodazole and saponin were purchased from Sigma-Aldrich.

**Western Blot and Immunofluorescence**

Western blotting was performed on whole-cell lysates as described by the manufacturer (Upstate Biotechnology, NY). The antibodies used for Western blotting and Immunofluorescence included anti-EGFR antibody (Cell Signaling technologies, MA; Santa Cruz, CA; anti-HDAC6 antibodies (Millipore, MA); anti-EEA1 (Santa Cruz, CA); anti-LAMP2 (Developmental...
Figure 7. HDAC6 regulates EGFR intracellular transport. (A) mIMCD3 cells were serum-starved and then stimulated with 100 ng/ml EGF for indicated periods of time. The cells were then processed for double-labeling immunostaining with anti-EEA1 and anti-EGFR antibodies. Localization of EGFR to the EEA1-containing vesicles was analyzed. (B) PN24 cells were serum-starved and then stimulated with 100 ng/ml EGF for indicated periods of time. The cells were then processed for immunostaining as in (A). Localization of EGFR to the EEA1-containing vesicles was analyzed. (C) mIMCD3 cells were processed for double-labeling immunostaining with anti-LAMP2 and anti-EGFR antibodies. Co-localization of EGFR to LAMP-2-containing vesicles was examined. (D) PN24 cells were processed for double-labeling immunostaining with anti-LAMP2 and anti-EGFR antibodies. Co-localization of EGFR to LAMP-2-containing vesicles was examined. *p < 0.05.
doi:10.1371/journal.pone.0049418.g007

Figure 8. Microtubule stability affected EGF induced EGFR degradation. (A) and (B) Influence of nocodazole on EGF-induced EGFR degradation. Pkd1 wild-type (WT) MEK cells (A) and Pkd1<sup>+/−/−</sup> (Null) MEK cells (B) were pretreated with 10 μg/ml cycloheximide for 2 hours. Pretreated cells were treated with 0.2 μg/ml nocodazole and/or 100 ng/ml EGF for another 2 hours. EGF-induced EGFR degradation was strikingly attenuated after co-treatment with EGF and nocodazole, which disturbed the stability of microtubule. *p < 0.05. **p < 0.01.
doi:10.1371/journal.pone.0049418.g008
Studies Hybridoma Bank); anti-acetylated-α-tubulin, anti-actin antibody (Sigma, MO). Donkey-anti-rabbit, donkey-anti-mouse, donkey-anti-goat IgG-horseradish peroxidase (Santa Cruz, CA) were used as secondary antibodies for Western blotting. EGF-Alexa Fluor 488 was purchased from Invitrogen (Invitrogen, CA). Fluro488-conjugated anti-mouse and anti-rabbit IgG antibody, Fluro555-conjugated anti-mouse, anti-rabbit, anti-goat, anti-rat IgG antibody (Invitrogen, CA) were used as secondary antibodies for immunofluorescence. Immunofluorescence images were obtained with a NIKON ECLIPSE 80i Microscope. For saponin treatment, cells were first rinsed with cold PBS three times and incubated with 0.005% (w/v) saponin that was made freshly in 4°C PBS. Saponin treatment lasted 5 min on ice and was stopped by quickly rinsing the cells three times with cold PBS. Then regular immunostaining procedures were applied. For EGF treatment, cells were serum-starved overnight and then treated with EGF (100 ng/ml) or EGF-Alexa Fluor 488 (80 ng/ml).

**HDAC6 Knockdown by Lentivirus Carrying HDAC6 shRNA**

HEK293T cells were cotransfected with lentiviral plasmid pGIPZ-siHDAC6 or control empty vector pGIPZ-NS, pPAX2 packaging plasmid, and pMD2.G envelope plasmid using calcium phosphate. Twelve hours later, medium containing the transfection reagent was removed and replaced with fresh complete DMEM medium plus 10% FBS and penicillin/streptomycin. Forty-eight hours later, cultures containing lentiviral particles were harvested from HEK293T cells. Pkd1 wild type and mutant MEK cells and PN24 cells were then infected with appropriate amounts of lentiviral particles together with 5 μg/ml polybrene (Sigma, MO). Twenty-four hours later, virus-containing medium was removed and replaced with fresh medium plus 5 μg/ml puromycin. Two days after selection, all the cells are GFP positive, which indicates the efficiency of transduction. Five days after infection, cells were harvested and analyzed by Western blot to examine the efficiency of HDAC6 knockdown.

**Quantitative Reverse-transcription Polymerase Chain Reaction**

HDAC6 was stable knockdown in Pkd1 mutant (Null) MEK cells. Cells were washed quickly with PBS, and total RNA was extracted using the RNeasy plus mini kit (Qiagen Germanton, MD). One micrograms of total RNA were used for reverse transcription reactions in a 20 μl reaction to synthesize cDNA using Iscript cDNA synthesis kit (BioRad, Hercules, CA). RNA expression profile was analyzed by real-time PCR using iTaq SYBER Green supermix with ROX (BioRad) and carried in an
icycler iQTM Real-time PCR detection system. Genes were amplified using the following primers. EGFR-F: 5'-AT-CAAAGTTCTGGGTTCGGG-3'; EGFR-R: 5'-GTTGGCTTTTGGAGATGTGG-3'; Actin-F: 5'-AAGAGCTATGAGCTGCCTGA-3'; Actin-R: 5'-TACGGATGTCAACGTCACAC-3'. The complete reactions were subjected to the following program of thermal cycling: 40 cycles of 10s at 95°C and 20s at 63°C, a melting curve was run after the PCR cycles, followed by a cooling step. Each sample was run in triplicated in every experiment, and each experiment was repeated three times. The expression level of EGFR was normalized to the expression level of actin.

Mouse Strain and Treatment

Pkd1<sup>nl</sup> mice were generated as described.[23] Homozygous Pkd1<sup>nl</sup> mice, with only 13–20% normally spliced Pkd1 transcripts caused by an intronic neomycin-selectable marker, are viable, showing bilaterally enlarged polycystic kidneys. Pkd1<sup>fl/fl</sup>:Ksp-cre mice were generated as described.[28] Each Pkd1<sup>fl/fl</sup>:Ksp-cre pup was injected with 0.5 μg/g TSA or DMSO (control) daily from postnatal day 3 (P3) to P6. All the kidneys were harvested at postnatal day 7 (P7) for further analysis.

Immunohistochemistry

For HDAC6 staining, kidneys were fixed with 4% paraformaldehyde overnight. Polyclonal goat anti-HDAC6 antibody (1:40, Santa Cruz, CA), a peroxidase conjugate secondary antibody (1:200, Sigma, MO), and DAB (3,3'-diaminobenzidine tetrahydrochloride) substrate system were used. For EGFR staining, kidneys were fixed with 4% paraformaldehyde for 60 min at 4°C, then stepwise dehydrated in acetone, and embedded in resin blocks using a Immuno-Bed Kit (Polyscience Inc., Warrington, PA). 3 μM sections were then cut, and immunohistochemical staining of the EGFR was conducted using the rabbit polyclonal anti-EGFR antibody (Abcam, Cambridge, UK) (1:50). Images were analyzed with a NIKON ECLIPSE 80i Microscope.

HDAC6 Enzymatic Activity Assay

The measurement of HDAC6 activity from cell lysates of Pkd1 wild type, heterozygous and homozygous renal epithelial cell lines
was carried out with a commercially available assay kit (Cayman Chemical, Ann Arbor, MI) with modification. In brief, sub-confluent cells were washed twice and collected in PBS. Cells were solubilized with 20 mM Tris/HCl buffer (pH 7.5) containing 157 mM NaCl, 2 mM EDTA, 10% glycerol, 1% Triton x-100 and protease inhibitor cocktail (Roche Molecular Biochemicals, Indianapolis, IN). Cell lysates from different cell types were incubated on ice for 10 min followed by sonication, and then centrifuged at 16000 g for 15 min at 4°C. Same amount of cell lysates (2 μg) from different cell types were then incubated with anti-HDAC6 antibody pre-coupled beads, in that anti-HDAC6 antibody (Santa Cruz Biotech, SC-5258) was coupled to 20% protein G agarose beads (GE Healthcare Life Sciences) in PBS in the presence of 5 mg/ml bovine serum albumin (Sigma, MO) for 6 hours at 4°C, overnight at 4°C. The next day, immunocomplex beads were washed four times with lysis buffer and resuspended in 140 μl HDAC assay buffer. Each immunoprecipitant was incubated with 200 μM acetylated fluorescent substrate in HDAC6 assay buffer at 37°C. After 30 min, the lysine developer was added, and the mixture was incubated for another 15 min at room temperature. The enzyme activity was monitored using a fluorometric assay. Fluorescence was measured using a TECAN infinite M200 PRO microplate reader (Tecan, Research Triangle Park, NC) with excitation at 360 nm and emission at 460 nm.

References

1. Harris PC, Torres VE (2009) Polycystic kidney disease. Annu Rev Med 60: 321–337.
2. Torres VE, Harris PC (2009) Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int 76: 149–168.
3. Wilson PD (2004) Polycystic kidney disease. N Engl J Med 350: 151–164.
4. Melenhorst WR, Mulder GM, Xi Q, Hoendervogel JG, Kimura K, et al. (2008) Epidermal growth factor receptor signaling in the kidney: key roles in physiology and disease. Hypertension 52: 987–993.
5. Du J, Wilson PD (1995) Abnormal polarization of EGF receptors and autocrine stimulation of cyst epithelial growth in human ADPKD. Am J Physiol 269: C487–495.
6. Orritiana SA, Sweeney WE, Neff CD, Avner ED (1995) Epidermal growth factor receptor expression is abnormal in murine polycystic kidney. Kidney Int 47: 490–499.
7. Richards WG, Sweeney WE, Yoder BK, Wilkinson JE, Woychik RP, et al. (1998) Epidermal growth factor receptor activity mediates renal cyst formation in polycystic kidney disease. J Clin Invest 101: 935–939.
8. Sweeney WE Jr, Avner ED (1998) Functional activity of epidermal growth factor receptor factor receptors in autosomal recessive polycystic kidney disease. Am J Physiol 275: F307–309.
9. Li X (2011) Epigenetics and autosomal dominant polycystic kidney disease. Biochim Biophys Acta 1812: 1231–1238.
10. Zeng F, Singh AB, Harris RC (2009) The role of the EGF family of ligands and receptors in renal development, physiology and pathophysiology. Exp Cell Res 315: 602–610.
11. Sweeney WE, Chen Y, Nakanishi K, Frost P, Avner ED (2000) Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor. Kidney Int 57: 33–40.
12. Nauta J, Sweeney WE, Rutledge JC, Avner ED (1995) Biliary epithelial cells from mice with congenital polycystic kidney disease are hyperresponsive to epidermal growth factor. Pediatr Res 37: 755–763.
13. Sweeney WE Jr, Avner ED (2006) Molecular and cellular pathophysiology of autosomal recessive polycystic kidney disease (ARPKD). Cell Tissue Res 326: 671–685.
14. Wang Z, Zhang L, Yeung TK, Chen X (1999) Endocytosis deficiency of epidermal growth factor (EGF) receptor-ErbB2 heterodimers in response to EGF stimulation. Mol Biol Cell 10: 1621–1636.
15. Torres VE, Sweeney WE Jr, Wang X, Qian Q, Harris PC, et al. (2003) EGF receptor tyrosine kinase inhibition attenuates the development of PKD in HanSPRD rats. Kidney Int 64: 1573–1579.

Statistics

Data are presented as mean ± Standard error. An unpaired 2-tailed student’s t test was used to determine the significant differences. A P value less than 0.05 is considered significant.

Ethics Statement

This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Institutional Animal Care and Use Committee (IACUC) of Medical College of Wisconsin (Permit Number: AUA1152).

Acknowledgments

We are grateful for cell lines PH2 and PN24 provided by Dr. S. Somlo through the George M O’Brien Kidney Center at Yale University, NIH grant P30 DK079310.

Author Contributions

Conceived and designed the experiments: XL. Performed the experiments: WL, LXF, XZ. Analyzed the data: WL, LXF, XZ. Wrote the paper: XL. Provided feedback on the manuscript: EDA WES.